Sirio Pharma Co., Ltd.

SZSE:300791 Stock Report

Market Cap: CN¥6.4b

Sirio Pharma Valuation

Is 300791 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300791 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300791 (CN¥27.36) is trading below our estimate of fair value (CN¥72.05)

Significantly Below Fair Value: 300791 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300791?

Key metric: As 300791 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300791. This is calculated by dividing 300791's market cap by their current earnings.
What is 300791's PE Ratio?
PE Ratio19.1x
EarningsCN¥335.69m
Market CapCN¥6.41b

Price to Earnings Ratio vs Peers

How does 300791's PE Ratio compare to its peers?

The above table shows the PE ratio for 300791 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average33.6x
603193 Runben Biotechnology
32.5x22.7%CN¥9.9b
605009 Hangzhou Haoyue Personal Care
14.5x16.4%CN¥6.1b
001328 Dencare (Chongqing) Oral Care
34.1x17.4%CN¥5.2b
301507 Hangzhou Minsheng Healthcare
53.2xn/aCN¥4.8b
300791 Sirio Pharma
19.1x21.1%CN¥6.4b

Price-To-Earnings vs Peers: 300791 is good value based on its Price-To-Earnings Ratio (19.1x) compared to the peer average (33.6x).

Price to Earnings Ratio vs Industry

How does 300791's PE Ratio compare vs other companies in the CN Personal Products Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300791 19.1xIndustry Avg. 33.9xNo. of Companies4PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300791 is good value based on its Price-To-Earnings Ratio (19.1x) compared to the CN Personal Products industry average (33.9x).

Price to Earnings Ratio vs Fair Ratio

What is 300791's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300791 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.1x
Fair PE Ratio24.1x

Price-To-Earnings vs Fair Ratio: 300791 is good value based on its Price-To-Earnings Ratio (19.1x) compared to the estimated Fair Price-To-Earnings Ratio (24.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300791 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥27.36
CN¥31.53
+15.3%
6.3%CN¥34.50CN¥29.50n/a4
Nov ’25CN¥26.46
CN¥31.53
+19.2%
6.3%CN¥34.50CN¥29.50n/a4
Oct ’25CN¥30.24
CN¥31.33
+3.6%
7.2%CN¥34.50CN¥29.50n/a3
Sep ’25CN¥23.79
CN¥29.75
+25.1%
0.8%CN¥30.00CN¥29.50n/a2
Aug ’25CN¥22.53
CN¥32.05
+42.3%
3.0%CN¥33.08CN¥30.77n/a3
Jul ’25CN¥25.80
CN¥32.05
+24.2%
3.0%CN¥33.08CN¥30.77n/a3
Jun ’25CN¥30.00
CN¥32.05
+6.8%
3.0%CN¥33.08CN¥30.77n/a3
May ’25CN¥30.02
CN¥32.05
+6.8%
3.0%CN¥33.08CN¥30.77n/a3
Apr ’25CN¥28.15
CN¥29.74
+5.7%
12.2%CN¥32.31CN¥24.62n/a3
Mar ’25CN¥24.45
CN¥29.90
+22.3%
10.5%CN¥32.31CN¥24.62n/a4
Feb ’25CN¥21.95
CN¥29.90
+36.2%
10.5%CN¥32.31CN¥24.62n/a4
Jan ’25CN¥26.66
CN¥27.50
+3.1%
10.5%CN¥30.38CN¥24.62n/a2
Dec ’24CN¥27.23
CN¥27.50
+1.0%
10.5%CN¥30.38CN¥24.62n/a2
Nov ’24CN¥25.29
CN¥27.50
+8.7%
10.5%CN¥30.38CN¥24.62CN¥26.462
Oct ’24CN¥19.86
CN¥28.65
+44.3%
6.0%CN¥30.38CN¥26.92CN¥30.242
Sep ’24CN¥20.53
CN¥28.65
+39.6%
6.0%CN¥30.38CN¥26.92CN¥23.792

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

SYoung Group

CN¥5.0b

Engages in the research and development, production, and sale of cosmetic products in China.

300740

CN¥12.95

7D

-6.8%

1Y

-21.8%

Byhealth

CN¥21.7b

Develops and sells dietary supplements.

300146

CN¥12.89

7D

-5.0%

1Y

-29.8%

Sirio Pharma

CN¥6.4b

Operates as a contract manufacturer for dietary supplement industry worldwide.

300791

CN¥27.36

7D

-3.5%

1Y

6.2%